212 related articles for article (PubMed ID: 26044191)
1. NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5.
Foster KA; Jane EP; Premkumar DR; Morales A; Pollack IF
Int J Oncol; 2015 Aug; 47(2):506-16. PubMed ID: 26044191
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells.
Jane EP; Premkumar DR; Morales A; Foster KA; Pollack IF
J Pharmacol Exp Ther; 2014 Jul; 350(1):22-35. PubMed ID: 24741074
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
Kim EH; Yoon MJ; Kim SU; Kwon TK; Sohn S; Choi KS
Cancer Res; 2008 Jan; 68(1):266-75. PubMed ID: 18172319
[TBL] [Abstract][Full Text] [Related]
4. KAAD-cyclopamine augmented TRAIL-mediated apoptosis in malignant glioma cells by modulating the intrinsic and extrinsic apoptotic pathway.
Siegelin MD; Siegelin Y; Habel A; Rami A; Gaiser T
Neurobiol Dis; 2009 May; 34(2):259-66. PubMed ID: 19385057
[TBL] [Abstract][Full Text] [Related]
5. The flavonolignan silibinin potentiates TRAIL-induced apoptosis in human colon adenocarcinoma and in derived TRAIL-resistant metastatic cells.
Kauntz H; Bousserouel S; Gossé F; Raul F
Apoptosis; 2012 Aug; 17(8):797-809. PubMed ID: 22555452
[TBL] [Abstract][Full Text] [Related]
6. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
Röhn TA; Wagenknecht B; Roth W; Naumann U; Gulbins E; Krammer PH; Walczak H; Weller M
Oncogene; 2001 Jul; 20(31):4128-37. PubMed ID: 11464279
[TBL] [Abstract][Full Text] [Related]
7. Phenethyl isothiocyanate sensitizes glioma cells to TRAIL-induced apoptosis.
Lee DH; Kim DW; Lee HC; Lee JH; Lee TH
Biochem Biophys Res Commun; 2014 Apr; 446(4):815-21. PubMed ID: 24491546
[TBL] [Abstract][Full Text] [Related]
8. Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand.
Nagane M; Cavenee WK; Shiokawa Y
J Neurosurg; 2007 Mar; 106(3):407-16. PubMed ID: 17367063
[TBL] [Abstract][Full Text] [Related]
9. Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway.
Premkumar DR; Jane EP; Foster KA; Pollack IF
J Pharmacol Exp Ther; 2013 Aug; 346(2):201-10. PubMed ID: 23740602
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.
Hetschko H; Voss V; Seifert V; Prehn JH; Kögel D
FEBS J; 2008 Apr; 275(8):1925-36. PubMed ID: 18341587
[TBL] [Abstract][Full Text] [Related]
11. Lipoxygenase inhibitor MK886 potentiates TRAIL-induced apoptosis through CHOP- and p38 MAPK-mediated up-regulation of death receptor 5 in malignant glioma.
Woo JS; Kim SM; Jeong CH; Ryu CH; Jeun SS
Biochem Biophys Res Commun; 2013 Feb; 431(2):354-9. PubMed ID: 23261452
[TBL] [Abstract][Full Text] [Related]
12. Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway.
Cha Z; Cheng J; Xiang H; Qin J; He Y; Peng Z; Jia J; Yu H
Cancer Chemother Pharmacol; 2019 Oct; 84(4):719-728. PubMed ID: 31281953
[TBL] [Abstract][Full Text] [Related]
13. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
14. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
15. Co-administration of ABT-737 and SAHA induces apoptosis, mediated by Noxa upregulation, Bax activation and mitochondrial dysfunction in PTEN-intact malignant human glioma cell lines.
Foster KA; Jane EP; Premkumar DR; Morales A; Pollack IF
J Neurooncol; 2014 Dec; 120(3):459-72. PubMed ID: 25139025
[TBL] [Abstract][Full Text] [Related]
16. Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation.
Yoon MJ; Kang YJ; Kim IY; Kim EH; Lee JA; Lim JH; Kwon TK; Choi KS
Carcinogenesis; 2013 Aug; 34(8):1918-28. PubMed ID: 23615398
[TBL] [Abstract][Full Text] [Related]
17. Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation.
Kim JY; Kim EH; Kim SU; Kwon TK; Choi KS
Carcinogenesis; 2010 Mar; 31(3):367-75. PubMed ID: 19939880
[TBL] [Abstract][Full Text] [Related]
18. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.
Kaliberov S; Stackhouse MA; Kaliberova L; Zhou T; Buchsbaum DJ
Gene Ther; 2004 Apr; 11(8):658-67. PubMed ID: 14973547
[TBL] [Abstract][Full Text] [Related]
19. IFN‑β sensitizes TRAIL‑induced apoptosis by upregulation of death receptor 5 in malignant glioma cells.
Yoshimura S; Sano E; Hanashima Y; Yamamuro S; Sumi K; Ueda T; Nakayama T; Hara H; Yoshino A; Katayama Y
Oncol Rep; 2019 Dec; 42(6):2635-2643. PubMed ID: 31638255
[TBL] [Abstract][Full Text] [Related]
20. Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation.
Kim IY; Kang YJ; Yoon MJ; Kim EH; Kim SU; Kwon TK; Kim IA; Choi KS
Neuro Oncol; 2011 Mar; 13(3):267-79. PubMed ID: 21292685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
